Cantor Fitzgerald has raised its price target for PTC Therapeutics, the US-based biopharmaceutical company, pointing to an improving outlook for its gene therapy Sephience. The investment bank's revised valuation reflects expectations that the treatment could gain broader traction in European markets, where regulatory decisions are anticipated later this year.
Sephience (eladocagene exuparvovec) is designed to treat aromatic L-amino acid decarboxylase (AADC) deficiency, a rare inherited disorder that severely impairs motor function and development. The therapy has already received approval in the United States and parts of Europe, but analysts believe a wider reimbursement footprint could significantly boost revenues. Cantor Fitzgerald's upgrade comes as PTC Therapeutics continues to engage with health authorities across the EU on pricing and access.
For UK investors, the news highlights the growing influence of gene therapies on biotech valuations. While PTC Therapeutics is listed on the Nasdaq, its performance often ripples through London-listed funds and exchange-traded products that hold US healthcare stocks. Pension schemes with exposure to global equity funds may also feel the effects if the stock gains further momentum on positive regulatory outcomes.
The broader biotech sector has seen renewed interest this year, driven by advances in rare disease treatments and gene editing. However, analysts caution that commercial adoption of such therapies remains uneven, with reimbursement negotiations often protracted. Cantor Fitzgerald's price target adjustment suggests confidence that Sephience can overcome these hurdles, but UK holders should be aware that regulatory timelines remain a key risk factor.
PTC Therapeutics has not yet commented on the revised target. The company's next major catalyst is expected to be a European Medicines Agency decision on expanded labelling for Sephience, which could come within the next few months. Investors are also watching for updates on the firm's pipeline of other rare disease programmes.